Skip to main content

Table 2 Baseline variables predictive of WPAI:SHP subscales at 6 and 12 months in 1003 AS patients

From: Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients

Predictor

Odds ratio (95% CI)

 Outcome: absenteeism

 

  Fatigue

1.18 (0.92 to 1.51)

  % work time missed due to AS (> 0 vs 0)

4.59 (2.91 to 7.25)

  Anxiety/depression

Some vs none

1.77 (1.12 to 2.80)

Extreme vs none

0.87 (0.26 to 2.86)

Extreme vs some

0.49 (0.15 to 1.57)

  Visit 12 months vs 6 months

1.001 (0.70 to 1.44)

Predictor

Standardized beta-coefficient (β) (95% CI)

 Outcome: presenteeism

 

  Fatigue

3.75 (2.14 to 5.36)

  Male vs female

−4.65 (−7.62 to −1.68)

  Age (years)

4.48 (3.07 to 5.89)

  CRP

−1.83 (−3.53 to −0.13)

  % impairment while working due to AS

6.25 (4.67 to 7.82)

  Visit 12 months vs 6 months

−0.99 (−2.57 to 0.60)

 Outcome: Work productivity loss

  Fatigue

1.81 (−0.40 to 4.02)

  Male vs female

−3.57 (−7.29 to 0.15)

  Age (years)

5.22 (3.52 to 6.93)

  Pain

2.77 (0.34 to 5.20)

  Pain at 12 months vs pain at 6 months

−2.49 (−4.49 to −0.49)

  % overall work impairment due to AS

6.62 (4.53 to 8.71)

  Anxiety/depression

Some vs none

3.76 (0.09 to 7.42)

Extreme vs none

12.32 (1.38 to 23.26)

  Visit 12 months vs 6 months

−1.42 (−3.42 to 0.59)

 Outcome: Activity impairment

  Fatigue

2.62 (1.26 to 3.98)

  Age (years)

5.07 (3.96 to 6.19)

  CRP

−2.76 (−3.85 to −1.67)

  % activity impairment due to AS

8.51 (7.14 to 9.87)

  Anxiety/depression

Some vs none

3.27 (0.85 to 5.68)

Extreme vs none

10.74 (5.35 to 16.14)

  Visit 12 months vs 6 months

−1.10 (−2.35 to 0.15)

  1. AS, ankylosing spondylitis; CI, confidence interval; CRP, C-reactive protein; RA, rheumatoid arthritis; VAS, visual analogue scale; WPAI:SHP, Work Productivity and Activity Impairment—Special Health Problems